Compare GPI & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPI | ICUI |
|---|---|---|
| Founded | 1995 | 1984 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail-Auto Dealers and Gas Stations | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | 1997 | 1995 |
| Metric | GPI | ICUI |
|---|---|---|
| Price | $337.91 | $125.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $442.63 | $182.25 |
| AVG Volume (30 Days) | 155.0K | ★ 244.5K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ 100.62 |
| EPS | ★ 25.24 | 0.03 |
| Revenue | ★ $11,123,721,000.00 | $2,231,262,000.00 |
| Revenue This Year | $3.64 | N/A |
| Revenue Next Year | $3.08 | $4.46 |
| P/E Ratio | ★ $13.39 | $4,180.00 |
| Revenue Growth | ★ 2.17 | N/A |
| 52 Week Low | $292.44 | $107.02 |
| 52 Week High | $488.39 | $160.29 |
| Indicator | GPI | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 59.44 | 43.64 |
| Support Level | $324.49 | $122.17 |
| Resistance Level | $347.81 | $133.62 |
| Average True Range (ATR) | 10.37 | 4.23 |
| MACD | 2.74 | 0.59 |
| Stochastic Oscillator | 67.23 | 45.19 |
Group 1 owns and operates 32 collision centers and 254 automotive dealerships in the US and the UK, offering 36 brands of automobiles altogether. Slightly over half of the stores are in the US with locations mostly in metropolitan areas in 17 states in the Northeast, Southeast, Midwest, and California. Texas alone contributed 31.6% of new-vehicle unit volume in 2025 and the UK 27.6%. Texas, Massachusetts, and California combined was 45.4%. Revenue in 2025 totaled $22.6 billion. The firm entered the UK in 2007 and has 109 stores there contributing about 26% of total revenue. Group 1 was founded in 1995 and is based in Houston.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.